AstaMed MYO is a prescription medical food for the clinical dietary management of sarcopenia. The formulation consists of proprietary natural astaxanthin as well as natural tocotrienols, zinc and vitamin D3.

AstaMed MYO is a prescription medical food for the clinical dietary management of sarcopenia. The formulation consists of proprietary natural astaxanthin as well as natural tocotrienols, zinc and vitamin D3.

Sarcopenia is the degenerative loss of skeletal muscle. In sarcopenia, muscle mass, quality, and strength progressively decreases beyond the normal aging process, compromising physical function and independence, increasing risk of disability, and lowering quality of life in older adults. Although it is estimated that sarcopenia affects approximately 45% of the U.S. senior population and exceeds $18 billion in direct healthcare costs, there are no approved pharmaceutical drugs for the treatment of sarcopenia.

Astavita recently announced preliminary results of a randomized, double-blind, placebo-controlled clinical study at the University of Washington, showing patients with sarcopenia significantly improved muscle strength as a result of receiving 30 days of AstaMed MYO natural astaxanthin without any lifestyle modifications or additional exercise protocols. The ongoing study is designed to explore the effectiveness of AstaMed MYO among adult patients with sarcopenia who have impaired muscle function. Final results are anticipated in Q4′ 2016 or Q1′ 2017.

AstaMed, a division of Astavita, Inc., has recently entered into an agreement with Symplmed Technologies a private medical company that markets, sells and distributes its products directly to physicians, patients and care providers.

AstaMed-Direct will also accept insurance plans and provide delivery directly to a patient’s home and automate reminders and refills. The program with launch October 1, 2016, in parallel with the new effective date of the ICD-10 diagnosis code for sarcopenia — M62.84.

“Partnering with Astavita to provide new options for helping to address the long term health requirements of people living with the debilitating effects of sarcopenia is another great opportunity to help patients and manufacturers,” said Erik Emerson, President and CEO of Symplmed Technologies. “Both companies are strategically positioned to deploy state-of-the art technology combined with ground breaking medicine to help prescribers and patients live healthier and happier lives.”